acute coronary syndrome (ACS) 4 . Baseline values of hs-CRP are indicative of metabolic state associated with athero-thrombotic events. The presence of hs-CRP within most athero-thrombotic plaque suggests that it may contribute to the pathogenesis and complication of cardiovascular disease 7, 8, 9 . High sensitive C-reactive protein (hs-CRP) binds to lipoprotein and activates proinflammatory complement 7, 8, 9 .
Ticagrelor, a comparatively recently introduced ADPreceptor inhibitor, is a member of the theienopyridine class of adenosine diphosphate (ADP) receptor inhibitors which reduces platelet aggregation by reversibly binding to ADP receptors on platelet membrane 7, 8, 9 . Compared to clopidogrel and prasugrel, ticagrelor inhibit adenosine diphosphate (ADP) induced platelet aggregation more rapidly and more consistently to a greater extent both in the healthy subjects and in patients with coronary artery disease including those undergoing percutaneous coronary intervention (PCI) 11 and reduce the risk of death either resulting from vascular cause, myocardial infraction (MI) or stroke 12 .
In acute coronary syndrome (ACS) inflammatory processes play active role leading to formation of atheroma. So if the antiplatelet drugs could exert anti-inflammatory effect, might be beneficial for the prevention of morbidity and mortality from cardiovascular diseases 13 .
In patients of ACS following PCI, the chance of thrombotic phenomenon is increased because of inflammatory reaction. In that situation an antiplatelet drug having antiinflammatory action could be a better option. Therefore the present study has been designed to compare the antiinflammatory properties of ticagrelor and clopidogrel in CSA patients following PCI.
Discussion and results:
Coronary artery disease is the major cause of mortality and morbidity worldwide 14 . Inflammation is a key etiological factor in the development of atherosclerotic disease and acute coronary syndromes (ACS) 4 , 15, 16 . Many inflammatory biomarkers have been studied as both prognostic indicators and possible intervention targets. Among these are the inflammatory biomarkers interleukin 6 (IL 6), High sensitive C-reactive protein (hs-CRP), myeloperoxidase (MPO), and soluble CD40 ligand (sCD40L), which represent pathophysiological steps in the inflammatory prosses that may contribute to the pathogenesis of ACS 17 . Ticagrelor and Clopidogrel both groups were almost identical in terms of their demographic characteristics (age and sex).The clinical characteristics (diabetes and hypertension) were also identically distributed between groups. The inflammatory marker high sensitive C-reactive protein was almost similar between the study groups. As most of the baseline characteristics were almost similar in distribution between groups, the outcome obtained could be considered due to intervention drugs.
Inflammation plays a role in the development of atherosclerosis and coronary heart disease 18 .Elevated markers of inflammation, particularly high sensitive CRP are associated with increased risk of cardiovascular events 19, 21, 22, 23 . Previously, the clinical benefits of antiplatelet therapy with the P2Y12 receptor inhibitor clopidogrel in ACS patients compared with placebo by reducing the cardiovascular deaths and nonfatal MI or stroke 20 . treatment with ticagrelor, the first revesrsibly binding oral P2Y12 receptor inhibitor, result s in greater inhibition of platelet aggregation than clopidogrel in patients with satable atheseclerotic disease or ACS 789 .Some studied suggest that an anti-inflammatory effect may contribute to the clinical efficacy of P2Y12 inhibitor .In this study we observed that hs-CRP was higher in CSA patients in baseline. After treatment the hs CRP was reduced from baseline to follow-up in ticagrerol group 19.7 mg/dl to 1.7 mg/dl (p value-0.001) and in clopidogrel group 18.4 mg/dl to 2 mg/dl (p value-0.001).
After 4 weeks of intervention, both groups showed significant reduction hsCRP indicating that antiinflammatory effect takes place in patients of CSA. However, summarizing the findings of the study, it is evident that both the antiplatelet drugs are effective in improving the status inflammatory marker but ticagrelor seems to be better than the clopidogrel.
Conclusion:
From the findings of the study, it appears that both ticagrelor and clopidogrel are effective in improving the status of inflammatory marker resulting from inflammatory process caused by chronic stable angina. But in terms of outcome, ticagrelor could be considered better than the clopidogrel.
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